Compounds > palmitoyl dihydroxyacetone phosphate

Page last updated: 2024-12-08

palmitoyl dihydroxyacetone phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	167650
CHEBI ID	17868
MeSH ID	M0043968

Synonyms (17)

Synonym
palmitoyl dihydroxyacetone phosphate
1-palmitoylglycerone 3-phosphate
CHEBI:17868
hexadecanoyl dihydroxyacetone phosphate
palmitoyl glycerone phosphate
2-oxo-3-(phosphonooxy)propyl hexadecanoate
17378-38-0
hexadecanoic acid 2-oxo-3-(phosphonooxy)propyl ester
C01192
palmitoylglycerone phosphate
(2-oxo-3-phosphonooxypropyl) hexadecanoate
LMGP00000063
1-hexadecanoyl-glycerone 3-phosphate
DTXSID30169654
1-palmitoyl-dihydroxyacetone-phosphate
Q27102677
hexadecanoic acid, 2-oxo-3-(phosphonooxy)propyl ester

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
1-acylglycerone 3-phosphate	A glycerone 3-phosphate having an unspecified O-acyl substituent at the 1-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

Pathway	Proteins	Compounds
Glycerophospholipid Metabolism	15	26
Choline Metabolism	18	27

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (40.00)	18.7374
1990's	5 (50.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.14 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.54 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dihydroxyacetone phosphate Dihydroxyacetone Phosphate: An important intermediate in lipid biosynthesis and in glycolysis.. dihydroxyacetone phosphate : A member of the class of glycerone phosphates that consists of glycerone bearing a single phospho substituent.	4.78	10	0	glycerone phosphates; primary alpha-hydroxy ketone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
dihydroxyacetone [no description available]	1.97	1	0	ketotriose; primary alpha-hydroxy ketone	antifungal agent; Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycolic acid glycolic acid: RN given refers to parent cpd. glycolic acid : A 2-hydroxy monocarboxylic acid that is acetic acid where the methyl group has been hydroxylated.	1.97	1	0	2-hydroxy monocarboxylic acid; primary alcohol	keratolytic drug; metabolite
cetyl alcohol cetyl alcohol: has been used for eczema, skin irritations; RN given refers to parent cpd; structure. hexadecanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of sixteen carbon atoms.. hexadecan-1-ol : A long-chain primary fatty alcohol that is hexadecane substituted by a hydroxy group at position 1.	1.98	1	0	hexadecanol; long-chain primary fatty alcohol	algal metabolite; flavouring agent; human metabolite; plant metabolite
1-palmitoyl-lysophosphatidic acid 1-palmitoyl-lysophosphatidic acid: RN given refers to parent cpd without isomeric designation. 1-palmitoylglycerol 3-phosphate : A monoacylglycerol phosphate having palmitoyl as the acyl group on O-1 and with the phosphate group on O-3.	1.98	1	0	2-lysophosphatidic acid
metrizamide Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.	1.96	1	0	amino sugar
flavin-adenine dinucleotide Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)	2	1	0	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group
nadp [no description available]	1.98	1	0
sodium borohydride sodium borohydride: RN given refers to parent cpd	1.96	1	0	inorganic sodium salt; metal tetrahydridoborate
flavin mononucleotide Flavin Mononucleotide: A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.	2	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	0	1.96	1	0
Adrenoleukodystrophy, Autosomal Neonatal Form [description not available]	0	2.9	1	0
Peroxisomal Disorders A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders.	0	2.9	1	0